Provectus Pharmaceuticals Inc. specializes in developing oncology and dermatology therapies. Its novel oncology drug, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The company has received orphan drug designations from the U.S. Food and Drug Administration for its melanoma and hepatocellular carcinoma indications. Its dermatological drug, PH-10, also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed phase 2 trials of PV-10.